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Abstract
Asthma is a heterogeneous disease that is typically characterized by chronic airway
inflammation and obstruction of airflow; it frequently presents in early childhood
and is the leading chronic disease in children in the western world. This review
presents a brief description of the pathophysiology of asthma and summarizes re‐
cent research results on the mechanisms of action of anti-asthma Chinese herbal
medicine commonly used in clinical practice. Other interventions of traditional Chi‐
nese medicine (TCM), such as acupuncture, tai chi, and meditation are also briefly
discussed. We believe that this contribution is theoretically and practically relevant
because the prevalence of asthma is increasing and, in addition to standard treat‐
ment, the use of complementary therapy is increasing and there is increasing scien‐
tific evidence demonstrating that TCM has potential for the treatment of childhood
asthma.
Keywords: Childhood asthma, traditional Chinese medicine, Acupuncture, complemen‐
tary and alternative medicine
1. Introduction
Asthma is a heterogeneous disease that is typically characterized by chronic airway inflam‐
mation and obstruction of airflow. Asthma is defined by a history of respiratory symptoms
such as wheezing, shortness of breath, chest tightness, and cough [1]. Both these symptoms
and airflow limitation characteristically vary over time as well as in intensity. These variations
are often triggered by external factors, such as exercise, allergen or irritant exposure, change
in the weather, or viral respiratory infections [2]. Symptoms and airway limitation may resolve
with or without medication and may sometimes be absent for weeks or months at a time.
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Asthma, a life-long condition, frequently presents in early childhood and is the leading chronic
disease in children in the Western world. Although the prevalence of childhood varies widely
across the world as described in the Phase III ISAAC study [3], most studies have reported
that this prevalence has increased in recent decades [4–6]. This increase has been associated
with a rise in atopic sensitization and other allergic disorders, such as eczema and rhinitis [6].
Approximately 25.9 million Americans (including 7.1 million children) had asthma in 2011,
which equates to a rate of 84.8 per 1,000 in the population. The highest prevalence rate was
seen in those in the 5–17 years of age bracket (105.5 per 1,000). Overall, the rate in those under
the age of 18 years (94.9 per 1,000) was significantly greater than that in those over 18 years
(81.6 per 1,000). The current asthma prevalence rate for boys under 18 years (101.7 per 1,000)
was 16% higher than the rate among similarly aged girls (87.8 per 1,000) [7]. In 2008, the
condition accounted for an estimated 14.4 million lost school days in children and 14.2 million
lost work days in adults. Asthma is thus a leading cause of activity limitation and amounts to
$56.0 billion in health care costs annually in the United States [7].
Approximately 80 percent of children with asthma develop symptoms before 5 years of age,
but the disease is frequently misdiagnosed or not suspected, particularly in infants [8].
Coughing and wheezing are the most common symptoms of childhood asthma. Breathless‐
ness, chest tightness or pressure, and chest pain have also been reported [1, 2]. Descriptors
may vary between cultures and by age; for example, children may be described as having
heavy breathing [2]. Confirmation of the diagnosis of asthma in children requires a careful
review of a child’s current and past medical history, family history, as well as a physical
examination.
Asthma is characterized by variable expiratory airflow limitation. Pulmonary function tests
are sometimes needed to diagnose asthma and to rule out other possible causes of the
symptoms. Spirometry is the most common pulmonary function test; it measures the flow and
volume of air blown out after a child takes a very deep breath and then forcefully exhales. The
important parameters derived from spirometry include forced expiratory volume in 1 s
(FEV1), forced vital capacity (FVC), flow between 25% and 75% of the vital capacity (FEF 25–
75%), and peak expiratory flow rate (PEFR) [9]. The greater the variation in lung function, or
the more times excess variation is seen in a patient with respiratory symptoms, the more likely
the diagnosis is to be one of asthma. The FEV1/FVC ratio is normally >0.75–0.80 and usually
exceeds 0.90 in children [10]. In asthma, at least once during diagnostic process, the FEV1 is
low, confirming that the FEV1/FVC ratio is reduced. Generally, an increase in FEV1 of >12% of
that predicted after inhalation of a rapid-acting bronchodilator and/or average daily diurnal
peak expiratory flow (PEF) variability exceeding 13% indicates that a child has asthma [2]. In
young children, in whom lung function testing is not feasible, including most preschool
children, asthma is defined by the presence of variable respiratory symptoms.
Traditional Chinese medicine (TCM), particularly herbal medicine, has been used for the
treatment of asthma for hundreds of years, as documented in the Yellow Emperor’s Inner
Canon (Huangdi Neijing) and the Essential Prescriptions from the Golden Cabinet (Jin Gui Yao Lue).
In Taiwan, Chinese herbal medicine is commonly used as complementary and alternative
therapy for the treatment of atopic diseases such as asthma, allergic rhinitis, and atopic
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dermatitis. The medicines used for the prevention and treatment of asthma have received
much attention in recent years. The cellular and molecular details of the underlying mecha‐
nisms of action of Chinese herbal medicine efficacious for treating asthma are just beginning
to be understood.
This chapter presents a brief description of the pathophysiology of asthma and summarizes
recent research results on the mechanisms of action of anti-asthma Chinese herbal medicine
commonly used in clinical practice. Other interventions of TCM, such as acupuncture, tai chi,
and meditation, are also briefly discussed.
2. Pathophysiology and pathogenesis of asthma
Asthma can be classified as atopic/allergic (extrinsic), which is the most common form, or
nonatopic/nonallergic (intrinsic) asthma, which is more rare, has a later onset, and tends to be
more severe than atopic asthma [11]. Atopic asthma involves inflammation mediated by
specific IgE antibodies directed against common environmental allergens, whereas nonatopic
asthma involves inflammation and airway constriction mediated by local production of IgE
antibodies that are possibly directed at bacterial or viral antigens. The pathophysiology of
nonatopic asthma is very similar to that of atopic asthma, but it is not caused by exposure to
an allergen [2, 11].
The gross pathology of asthma reveals significant overinflation of the lungs [12]. Microscopi‐
cally, this overinflation of lungs is manifest as marked distension of the alveoli. Notable airway
smooth muscle (ASM) hyperplasia, basement membrane thickening, mucous gland hyper‐
plasia, mucosal epithelium sloughing, and tissue edema are also seen [12]. This increase in
muscle mass, mucous gland tissues, and tissue edema leads to a thickened airway wall, with
a resultant decrease in airway caliber [12, 13]. These structural changes have been described
as remodeling, a term used to define complex morphological changes that involve all of the
structures of the bronchial wall [12, 13].
The initiation of bronchial epithelial damage by environmental agents (allergens, viruses,
irritants, etc.) or their inflammatory products activates a sequence of events that amplify the
inflammation and induce airway remodeling [13, 14]. Bousquet et al. suggested that asthma
pathophysiology involved overlapping interactions of smooth muscle dysfunction, airway
inflammation, and airway remodeling [13]. The inflammatory, physiological, and structural
factors that contribute to the pathogenesis of asthma will be described below.
2.1. Airway inflammation
Inflammation plays a central role in the pathophysiology of asthma [15]. Airway inflammation
remains a consistent pattern throughout the distinct phenotypes of asthma (e.g., intermittent,
persistent, exercise-associated, aspirin-sensitive, or severe asthma) [16]. Airway inflammation
involves an interaction of many cell types and multiple mediators with the airway, which
eventually results in the characteristic pathophysiological features of asthma. The principal
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cells involved in airway inflammation are mast cells, eosinophils, epithelial cells, macrophages,
and activated T lymphocytes [12, 13].
T lymphocytes play an important role in the regulation of airway inflammation through the
release of numerous cytokines. Airway inflammation in asthma may indeed represent a loss
of the normal balance between Th1 and Th2 lymphocytes [12, 16]. Th1 cells produce interleukin
(IL)-2 and interferon gamma (IFN-γ), which are critical in the defense mechanisms of cells in
response to infection. Th2 cells, in contrast, generate a family of cytokines (IL-4, IL-5, IL-6, IL-9,
and IL-13) that can stimulate the growth, differentiation, and recruitment of mast cells,
basophils, eosinophils, and B-cells, all of which are involved in humoral immunity and in the
allergic response [13, 14, 16].
IgE plays an essential role in type I hypersensitivity, which results in various allergic diseases,
such as allergic asthma, most types of sinusitis, allergic rhinitis, food allergies, and specific
types of chronic urticaria and atopic dermatitis [17]. Antigen-specific IgE is partly responsible
for the initiation of an allergic response in asthma. IgE primes the IgE-mediated allergic
response by binding to Fc receptors expressed on the surface of mast cells, basophils, eosino‐
phils, monocytes, macrophages, or platelets in humans [18]. Antigens cross-link to the IgE on
mast cells, which then release bronchoconstricting mediators (histamine, cysteinyl-leuko‐
trienes, prostaglandin D2) and further amplify the inflammatory response by damaging local
tissue and attracting other lymphocytes [17]. IL-4 produced by Th2 cells stimulates IgE
production in B-lymphocytes and expression of vascular cell adhesion molecule 1 (VCAM-1)
on endothelial cells, whereas IL-5 stimulates eosinophil differentiation and mobilization to
inflammatory sites [13, 16]. Circulating eosinophils enter the area of allergic inflammation and
begin migrating to the lung by rolling, through interactions with selectins, and eventually
adhere to the endothelium by means of binding between integrins and members of the
immunoglobulin superfamily of adhesion proteins, namely VCAM-1 and intercellular
adhesion molecule 1 (ICAM-1) [13, 16]. As the eosinophils enter the matrix of the airway
through the influence of various chemokines, such as monocyte chemotactic protein (MCP-1),
macrophage inflammatory protein (MIP-1α), eotaxin or RANTES, and cytokines, their survival
is prolonged by IL-4 and granulocyte-macrophage colony–stimulating factor (GM-CSF) [13,
16]. Upon activation, the eosinophils release inflammatory mediators, such as leukotrienes and
granule proteins, which injure airway tissues [19]. In addition, eosinophils can generate GM-
CSF to prolong and potentiate their survival and thereby contribute to persistent airway
inflammation [16]. Eosinophils are the most characteristic cells accumulated in asthma and
allergic inflammation; their presence is often related to disease severity. Eosinophils are
recruited or activated by IL-5, the eotaxin family of chemokines, via the eosinophil-selective
chemokine receptor CCR3, and by Toll-like receptors (TLRs). Activated eosinophils produce
lipid mediators, such as leukotrienes and platelet-activating factor, which mediate smooth
muscle contraction; toxic granule products (e.g., major basic protein, eosinophil-derived
neurotoxin, eosinophil peroxidase, or eosinophil cationic protein) that can damage airway
epithelium and nerves; and cytokines, such as GM-CSF, transforming growth factors (TGF)-
α and β, and interleukins, which may be involved in airway remodeling and fibrosis [13].
Recently, Th regulatory cells that exclusively produce IL-17 cytokines (TH17 cells) have been
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identified in patients with severe asthma [19]. The involvement of TH17 responses in the
pathogenesis of asthma has been shown by the overexpression of IL-17 mRNA in the airways
of asthma model mice [19]. It is now suggested that TH17-related cytokines play a critical role
in airway remodeling and may be involved in interactions with structural cells [13, 19].
2.2. Airway remodeling and ASM dysfunction
The histopathologic changes of airway remodeling include damage or loss of the normal
pseudostratified structure of airway epithelium, an increase in the proportion of mucous-
producing goblet cells, fibrotic thickening of the subepithelial reticular basement membrane
or “lamina reticularis,” increased numbers of myofibroblasts, increased vascularity, increased
ASM mass, and increased extracellular matrix [20]. These structural changes contribute to
bronchial wall thickening, alterations in the physiological consequences of smooth muscle
contraction, or loss of airway-parenchymal interdependence [13, 20].
Epithelial alterations in asthma include epithelial shedding, destruction of ciliated cells, goblet
cell hyperplasia, upregulation of growth factor release, and overexpression of receptors, such
as the epidermal growth factor receptors [21]. Loss of epithelial surface and the resultant
denudation of the basement membrane may decrease this protective effect, thereby increasing
the propensity for allergic insult to the airway [21]. A second important feature of airway
remodeling is subepithelial fibrosis, which has been consistently reported in asthma of all
levels of severity, in patients with atopic rhinitis, and even in children with treatment-resistant
asthma [21]. Subepithelial fibrosis occurs in the lamina reticularis, immediately below the
basement membrane, resulting in thickening of the basement membrane just below the
epithelium [22]. In the asthmatic airway, fibroblasts are activated and differentiate into
myofibroblasts, which secrete proinflammatory mediators and extracellular matrix proteins,
including collagens I, III, and V; fibronectin; tenascin; lumican; and biglycan [21, 22]. Asthmatic
airway fibroblasts promote fibrosis though expression of a higher ratio of tissue inhibitor of
metalloproteinase (TIMP)-2 to matrix metalloproteinase (MMP)-2, resulting in increased
matrix deposition [21]. MMPs are a family of proteases implicated in collagen degradation.
MMP-2, MMP-3, MMP-8, and MMP-9 have been associated with asthma [20]. Among these,
MMP-9 levels have been reported to be significantly higher in the sputum of patients with
asthma than in that of control subjects [20–23].
Respiratory ASM cells are the critical effector cells that modulate airway tone [22]. In asthmatic
airways, smooth muscle mass is increased due to a coordinated increase in the size (hyper‐
trophy) and number (hyperplasia) of ASM cells [21, 22]. ASM remodeling is considered to be
the primary cause of airway obstruction [21]. ASM cells participate in the inflammatory and
remodeling process through the expression of cellular adhesion molecules, receptors for
cytokines (e.g., TNF-α), chemokines (RANTES, eotaxin, MIP-1α, and IL-8), and TLRs [21].
Additionally, the migration of ASM cells toward the epithelium contributes to remodeling. A
wide range of inflammatory mediators, such as TNF-α, IL-1b, and IFN-γ, have been shown to
induce the expression of ICAM-1 and VCAM-1 on cultured ASM cells [21]. The surface
expression of cellular adhesion molecules by ASM cells might be pivotal in regulating
interactions with a variety of inflammatory cells, including eosinophils and T cells [21].
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Additionally, accumulating evidence has indicated an abnormal increase in the number and
size of microvessels within bronchial tissue in remodeled airways [21]. This occurs mainly
below the basal lamina, in the space between the muscle layer and the surrounding paren‐
chyma [21]. An imbalance between vascular endothelial growth factor (VEGF) and angiopoie‐
tin-1 has been shown to be involved in these abnormalities [21]. In fact, VEGF acts by increasing
the permeability of these abnormal blood vessels, resulting in vessel dilation and edema, which
contribute to airway narrowing [21, 22]. In addition to providing nutrition to the airways, these
vessels are the source of inflammatory cells and plasma-derived mediators and cytokines [21].
3. Conventional treatment of childhood asthma
The optimal treatment of childhood asthma depends upon a number of factors, including the
child’s age, the severity and frequency of asthma attacks, and the ability to properly use the
prescribed medications [2]. For the vast majority of children, asthma treatment can control
symptoms, allowing the child to participate fully in all activities, including sports. Identifying
and avoiding asthma triggers, the factors that set off or worsen asthma symptoms, are essential
for preventing asthma flare-ups [2]. Common asthma triggers generally include allergens
(such as dust, pollen, and furred animals), respiratory infections, irritants (such as tobacco
smoke, chemicals, and strong odors or fumes), physical activity, certain medicines (such as
beta blockers, aspirin, or other nonsteroidal anti-inflammatory medications), and emotional
stress [2]. After identifying potential triggers of asthma, the parent and health care provider
should develop a plan to deal with the triggers. If possible, the child should completely avoid
or limit exposure to the trigger [2].
The long-term goals of asthma management are to achieve good symptom control and to
minimize future risk of exacerbation, fixed airflow limitation, and side effects of treatment [2].
In control-based asthma management, pharmacological and nonpharmacological treatment is
adjusted continuously in a cycle that involves assessment, treatment, and review of the
response [2]. Asthma severity is determined by considering the following factors: the symp‐
toms reported over the previous 2 to 4 weeks, the current level of lung function (FEV1 and
FEV1/FVC values), and the number of instances of exacerbation requiring oral glucocorticoids
per year [2]. The classification of severity in children aged 5–11 years or in adolescents over
the age of 12 years is similar to that in adults [2]. The severity in children under the age of 4
years, however, is classified somewhat differently and includes intermittent, mild persistent,
moderate persistent, and severe persistent asthma [2].
3.1. Categories of asthma medications
Medication for asthma is mainly divided into two categories: controller medications and
reliever (rescue) medications [2]. Controller medications, such as inhaled corticosteroids (ICS)
and long-acting beta-adrenoceptor agonists (LABA), are used for regular maintenance
treatment [24–26]. These medications reduce airway inflammation, control symptoms, and
reduce future risks, such as exacerbations and decreased lung function. Reliever medications,
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such as short-acting beta-2-adrenoceptor agonists (SABA), are provided to all patients for as-
needed relief of breakthrough symptoms, including during worsening of asthma or exacer‐
bations [24–26]. They are also recommended for short-term prevention of exercise-induced
bronchoconstriction [2]. Reducing and, ideally, eliminating the need for reliever treatment are
both an important goal in asthma management and a measure of the success of asthma
treatment. Add-on therapies for patients with severe asthma may be considered when patients
have persistent symptoms and/or exacerbations, despite optimized treatment with high-dose
controller medications (usually a high-dose ICS and a LABA) and treatment of modifiable risk
factors [2].
The initiation of asthma therapy in a stable patient who is not already receiving medications
is based upon the severity of asthma in the individual. Patients with mild intermittent asthma
are best treated with an inhaled SABA, which should be taken as needed for the relief of
symptoms [2]. Patients in whom triggering of asthmatic symptoms can be predicted (e.g.,
exercise-induced bronchoconstriction) are encouraged to use their inhaled beta agonist
approximately 10 min prior to exposure, to prevent the onset of symptoms [2]. For mild
persistent asthma, the preferred long-term controller is a low-dose ICS [2]. Regular use of ICS
reduces the frequency of symptoms (and the need for SABAs for symptom relief), improves
the overall quality of life, and decreases the risk of serious exacerbations [2]. Alternative
strategies for treatment of mild persistent asthma include leukotriene receptor antagonists,
theophylline, and cromoglycate [2, 26].
For moderate persistent asthma, the preferred therapy is low doses of ICS plus an inhaled
LABA, or medium doses of ICS [2]. Alternative strategies include adding a leukotriene
modifier (leukotriene receptor antagonist or lipoxygenase inhibitor) or theophylline to low-
dose ICS [2]. For severe persistent asthma, the preferred treatments are medium (Step 4) or
high (Step 5) doses of ICS, in combination with an inhaled LABA [2]. In addition, for patients
who are inadequately controlled on high-dose ICS and LABAs, the anti-IgE therapy omalizu‐
mab may be considered, if there is objective evidence of sensitivity to a perennial allergen (by
allergy skin tests or in vitro measurements of allergen-specific IgE) and if the serum IgE level
is within the established target range [2].
4. Status and purpose
Currently, according to the guidelines published by the Global Initiative for Asthma (GINA),
conventional medicines are the mainstay for managing asthma; these include steroids, beta-2
adrenergic agonists, leukotriene modifiers, theophylline, and anti-IgE therapies [2]. However,
current conventional medications for childhood asthma are not yet satisfactory. The side effects
of long-term use of steroids and beta-2 adrenergic agonists are major concerns for parents, in
that growth, bone turnover, and adrenal gland function may be suppressed under, particularly
higher doses of steroids [24, 25]. Due to the chronic and potentially life-threatening nature of
asthma, and the lack of definitive preventive and curative therapies, many families look to
complementary and alternative medicine (CAM) for treatment. CAM is popular in the
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treatment of asthma and encompasses many therapies, including mind–body techniques,
nutritional manipulation, dietary and herbal supplements, TCM (including acupuncture),
exercise, manual therapies, and homeopathy [26]. Reportedly, CAM is commonly used in
children who have mild or moderate persistent asthma, those receiving high-dose ICS, and
patients who experience poor symptom control or require frequent physician visits, including
emergency room visits [26]. One retrospective longitudinal cohort study showed that initiation
of CAM treatment does not decrease future adherence to conventional asthma medications,
suggesting that alternative or integrative medicine use does not necessarily compete with
conventional asthma therapies [27]. As CAM use becomes more prevalent, it will become
increasingly important for physicians attending to asthmatic children to be aware of CAM use.
TCM is the major component of CAM therapies used in the United States and Taiwan. TCM
is one of the oldest medical practices in the world and has played an important role in
preventing and treating diseases in China for centuries, where it is still used as a monotherapy
or as part of an integrated medicine approach. Evidence has increased showing the efficacy of
TCM for the treatment of childhood asthma. Below, we explore complementary therapy,
involving TCM therapy for childhood asthma.
5. Chinese herbal formulas use in children with asthma
TCM formulas have been used to treat asthma for centuries. A number of well-controlled
clinical studies of several TCM formulas, including modified Mai-Men-Dong-Tang (mMMDT,
five herbs), Ding-Chuan-Tang (DCT, nine herbs), and STA-1 (the combination of Mai-Men-
Dong-Tang and Liu-Wei-Di-Huang-Wan, 10 herbs), and anti-asthma herbal medicine inter‐
vention (ASHMI, three herbs) provided evidence of clinical efficacy, safety, and
immunomodulatory effects [24]. Typically, the traditional TCM formulas that are prescribed
combine several single herbs to treat a specific disease. Recent research [25] from the National
Health Insurance Research Database (NHIRD) in Taiwan has revealed the core herbal treat‐
ments for children with asthma. The most commonly used herbal formulas for the treatment
of childhood asthma are Ma-Xing-Gan-Shi-Tang and Xiao-Qing-Long-Tang; the former is used
for excess heat congested in the lung, whereas the latter is used for the exterior wind-cold with
internal accumulation of retained fluid in the lung. These herbal formulas (shown in Table 1)
and several single herbs commonly used for the treatment of childhood asthma are described
below. The immunomodulatory effects of suppressing Th2 cells and decreasing subsequent
cytokine secretion of these herbal remedies will also be investigated. Other commonly
prescribed formulas that are used mainly to relieve asthma-related symptoms, such as
productive cough (Xing-Su-San, Zhi-Sou-San), coughing with a sore throat (Yin-Qiao-San),
and nasal congestion (Xin-Yi-Qing-Fei-Tang, Cang-Er-Zi-San, Shin-Yi-San), do not fall within
the scope of this review.
5.1. ASHMI
ASHMI is the first herbal medicine to receive approval for phase I and II clinical trials as a US
Food and Drug Administration investigational new drug (IND No. 71526) for treating asthma.
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Formula Composition Possible mechanisms
ASHMI
Ling Zhi (Ganoderma Lucidum), Ku Shen
(Radix Sophorae Flavescentis), and Gan Cao
(Radix Glycyrrhizae)
Decreases Th2 response; increases IFN-γ
levels; decreases IL-4, IL-5, IL-13, eotaxin,
TNF-α, total and specific IgE levels;
reduces AHR, mucous production,
neutrophilic and eosinophilic
inflammation; improves FEV1 and PEF
[24, 28–30]
Modified Mai-Men-Dong-
Tang (mMMDT)
Mai Men Dong (Radix Ophiopogonis), Ban
Xia (Rhizoma Pinelliae), American Ren Shen
(Radix Panacis Quinquefolii), Gan Cao (Radix
Glycyrrhizae), and Lantern Tridax (Herba
Tridacis procumbentis)
Antitussive effect, bronchial dilation via
beta-2 adrenergic effect; decreases IL-4,
total IgE, and specific IgE; reduces AHR;
improves FEV1 [24, 31–33]
STA-1
Mai Men Dong (Radix Ophiopogonis), Ban
Xia (Tuber Pinellia), American Ren Shen
(Radix Panacis Quinquefolii), Gan Cao (Radix
Glycyrrhizae), Shu Di Huang (Radix
Rehmanniae Preparata), Mu Dan Pi (Cortex
Moutan Radicis), Shan Zhu Yu (Fructus
Corni), Fu Ling (Poria), Ze Xie (Rhizoma
Alismatis), and Shan Yao (Radix Dioscoreae)
Reduces symptom scores, systemic
steroid dose, airway inflammation, AHR,
total IgE, and specific IgE; improves FEV1
[34, 35]
Ma-Xing-Gan-Shi-Tang
Ma Huang (Herba Ephedrae), Xing Ren
(Semen Armeniacae Amarum), Shi Gao
(Gypsum Fibrosum), and Gan Cao (Radix
Glycyrrhizae)
Antitussive effect, beta-2 adrenergic
effect; reduces neutrophilic inflammation
[36, 37]
Xiao-Qing-Long-Tang
Ma Huang (Herba Ephedrae), Gui Zhi
(Ramulus Cinnamomi), Ban Xia (Rhizoma
Pinelliae), Gan Jiang (Rhizoma Zingiberis), Xi
Xin (Herba Asari),Wu Wei Zi (Fructus
Schisandrae), Bai Shao Yao (Radix Paeoniae),
and Gan Cao (Radix Glycyrrhizae)
Decreases Th2 response; increases IFN-γ;
decreases IL-4, IL-5, IL-10, IL-13, IgE,
RANTES, eotaxin, and MCP-1 levels;
suppresses histamine release, reduces
airway inflammation, remodeling, and
immunomodulation; bronchial dilation,
partial beta-2 adrenergic effect [38–40]
Ding-Chuan-Tang
Ma Huang (Herba Ephedrae), Gan Cao
(Radix Glycyrrhizae), Ban Xia (Rhizoma
Pinelliae), Bai Guo (Semen Ginkgo), Kuan
Dong Hua (Flos Farfarae), Sang Bai Pi
(Cortex Moris), Su Zi (Fructus Perillae), Xing
Ren (Semen Armeniacae Amarum), and
Huang Qin (Radix Scutellariae)
Improves AHR, symptoms, and
medication; reduces eosinophilic
inflammation; beta-2 adrenergic effect
[41, 42]
Table 1. Herbal formulas frequently used for asthmatic children
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ASHMI is composed of the aqueous extracts of Ling Zhi (Ganoderma lucidum), Ku Shen (Sophora
flavescens), and Gan Cao (Glycyrrhiza uralensis) [24]. ASHMI improved lung function (FEV1),
reduced symptom scores, and decreased beta-2-adrenoceptor agonist use, to a degree similar
as that achieved by prednisone in adults with moderate to severe asthma, but without the
adverse effect of prednisone on adrenal function and with no overall immune suppression.
Individually, Ling Zhi, Ku Shen, and Gan Cao extracts and ASHMI (the combination of
individual extracts) inhibited production of IL-4 and IL-5 by murine memory Th2 cells and
that of eotaxin-1 by human lung fibroblast cells [28]. ASHMI synergistically inhibited eotaxin-1
production as well as Th2 cytokine production. In another mouse model of asthma, ASHMI
also reduced the levels of ovalbumin (OVA)-specific IgE and Th2 cytokines, including IL-4,
IL-5, and IL-13 in the lung, and increased IFN-γ secretion [29]. Moreover, ASHMI markedly
reduced airway hyperresponsiveness (AHR), mucous production, neutrophilic inflammation,
and TNF-α, IL-8, and IL-17 levels and also decreased eosinophilic inflammation and Th2
responses in vivo [30].
5.2. Modified Mai-Men-Dong-Tang
Mai-Men-Dong-Tang is a herbal TCM that has been used for the treatment of bronchitis,
bronchial asthma, and cough. The compositions of Mai-Men-Dong-Tang are Mai Men Dong
(Ophiopogon japonicus), Ban Xia (Pinellia ternata), Ren Shen (Panax ginseng), Gan Cao (Glycyrrhiza
uralensis), Da Zao (Ziziphus jujuba), and Geng Mi (Oryza sativa). Mai-Men-Dong-Tang was
shown to have an antitussive effect, based on improved airway clearance. The pharmacological
effect of this antitussive effect is suggested to involve the inhibition of C-fibers, bronchodila‐
tion, anti-inflammatory effects, suppression of mucosal excretion, and augmentation of
surfactant secretion [31]. Mai-Men-Dong-Tang was shown to potentiate beta-adrenergic
function in ASM, which may reflect the efficacy on AHR and asthma [32]. mMMDT contains
five herbs, including Mai Men Dong (Radix Ophiopogonis), Ban Xia (Rhizoma Pinelliae), Ameri‐
can Ren Shen (Radix Panacis Quinquefolii), Gan Cao (Radix Glycyrrhizae), and Lantern Tridax
(Herba Tridacis procumbentis) [33]. mMMDT was shown to decrease serum total IgE and house
dust mite-specific IgE significantly and downregulate the expression of IL-4 in allergen-
sensitized mice. The effect of mMMDT on changes in FEV1 was studied as the first efficacy end
point, given its validity for monitoring airway obstruction, which showed significant im‐
provement in FEV1 in patients treated with mMMDT [33]. Moreover, mMMDT also relieved
asthma symptoms, including coughing, wheezing, and breathlessness [33].
5.3. STA-1
STA-1 is a combination of mMMDT (four herbs) and Lui-Wei-Di-Huang-Wan (six herbs) [34].
The four herbs of mMMDT comprise Mai Men Dong (Radix Ophiopogonis), Ban Xia (Tuber
Pinellia), American Ren Shen (Radix Panacis Quinquefolii), and Gan Cao (Radix Glycyrrhizae)
without Lantern Tridax (Herba Tridacis procumbentis). The six herbs of Lui-Wei-Di-Huang-Wan
are Shu Di Huang (Radix Rehmanniae Preparata), Mu Dan Pi (Cortex Moutan Radicis), Shan Zhu
Yu (Fructus Corni), Fu Ling (Poria), Ze Xie (Rhizoma Alismatis), and Shan Yao (Radix Dioscor‐
eae). STA-1 was able to inhibit mite-induced IgE synthesis, reduce inflammation-associated
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accumulation of eosinophils and neutrophils in the airway, and relieve AHR in a murine model
[35]. Clinical evaluation of STA-1 in the treatment of mild-to-moderate chronic asthma
revealed a significant reduction of symptom scores, systemic steroid dose, total IgE, and
specific IgE in patients treated with STA-1 [34]. Furthermore, STA-1 also improved lung
function (FEV1) as compared with placebo after 6 months’ treatment and with only minimal
side effects [34].
5.4. Ma-Xing-Gan-Shi-Tang
Ma-Xing-Gan-Shi-Tang, a TCM, has been used in the treatment of bronchial asthma for several
centuries. Ma-Xing-Gan-Shi-Tang consists of Ma Huang (Herba Ephedrae), Xing Ren (Semen
Armeniacae Amarum), Shi Gao (Gypsum Fibrosum), and Gan Cao (Radix Glycyrrhizae). A murine
cough model, induced by sulfur dioxide gas, was used to investigate the antitussive effect of
Ma-Xing-Gan-Shi-Tang [36]. Both Ma Huang and Xing Ren inhibited cough induction in a
dose-dependent manner. However, Ma-Xing-Gan-Shi-Tang, which contains Ma Huang and
Xing Ren, showed stronger antitussive effects than the individual crude drugs [36]. In a guinea
pig model of allergic asthma, Ma-Xing-Gan-Shi-Tang was efficacious in stimulation of beta-2-
adrenoceptors on bronchial smooth muscle and had an anti-inflammatory effect, involving
inhibition of neutrophil infiltration into the airway [37]. Ma-Xing-Gan-Shi-Tang is typically
indicated in syndromes involving wind-heat on the lung or stagnated wind-cold that has
turned into heat and that stayed in the lung. In Taiwan, asthma triggered by respiratory tract
infection among asthmatic children is much more common than that triggered by cold
exposure and weather change. Asthma triggered by respiratory tract infection is the most
important indication for Ma-Xing-Gan-Shi-Tang [25].
5.5. Xiao-Qing-Long-Tang
Xiao-Qing-Long-Tang (XQLT) has been widely used clinically for the treatment of allergic
diseases, including bronchial asthma and allergic rhinitis. XQTL consists of Ma Huang (Herba
Ephedrae), Gui Zhi (Ramulus Cinnamomi), Ban Xia (Rhizoma Pinelliae), Gan Jiang (Rhizoma
Zingiberis), Xi Xin (Herba Asari), Wu Wei Zi (Fructus Schisandrae), Bai Shao Yao (Radix Paeo‐
niae), and Gan Cao (Radix Glycyrrhizae).
XQLT was shown to reduce bronchial inflammatory cell infiltration and airway remodeling
in repetitive Dermatogoides pteronyssinus-challenged mouse model of chronic asthma [38].
XQLT inhibited D. pteronyssinus-induced total IgE and D. pteronyssinus-specific IgG1 in serum
and changed the Th2-bios in bronchoalveolar lavage fluid (BALF) by inhibiting the activation
of nuclear factor-Kappa B (NF-κB). The same study also showed that XQLT treatment
increased the protein levels of IL-12, but decreased that of TNF-α, TGF-β1, IL-5, IL-6, and IL-13
by inhibiting expression of the genes including IL-10, IL-13, eotaxin, RANTES, and MCP-1 in
the lung. Moreover, collagen assays and histopathology indicated that XQLT reduces airway
remodeling in the lung [38]. XQLT treatment could inhibit the secretion of IL-5 in the serum
and downregulate mRNA expression of genes encoding eotaxin, RANTES, and MCP-1 in lung
tissues, which may contribute to a reduction in eosinophils and monocytes recruited to the
airway.
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Studies on the OVA-sensitized allergic airway inflammation model in mice revealed that
XQLT significantly inhibited the antigen-induced immediate asthmatic response and late
asthmatic response in actively sensitized mice. XQLT was shown to reduce the production
of Th2-associated cytokines, IL-4 and IL-5, and to restore the production of the Th1 cell-
associated cytokine, IFN-γ [39]. Anti-OVA IgE antibody levels were reduced in the BALF of
sensitized mice after oral administration of XQLT [39]. Furthermore, XQLT was shown to
have an anti-asthmatic effect, which is partly mediated by stimulation of beta-2-adrenocep‐
tors,  leading to bronchorelaxation;  furthermore,  XQLT inhibits  the infiltration of  eosino‐
phils into the airway [40].
5.6. Ding-Chuan-Tang
Ding-Chuan-Tang (DCT), another TCM, has been used in the treatment of bronchial asthma
for several centuries. DCT is composed of nine herbs, including Ma Huang (Herba Ephedrae),
Gan Cao (Radix Glycyrrhizae), Ban Xia (Rhizoma Pinelliae), Bai Guo (Semen Ginkgo), Kuan Dong
Hua (Flos Farfarae), Sang Bai Pi (Cortex Mori), Su Zi (Fructus Perillae), Xing Ren (Semen Arme‐
niacae Amarum), and Huang Qin (Radix Scutellariae). According to TCM principles, this
decoction is frequently prescribed for children with coughing, wheezing, and chest tightness.
One study of a murine OVA-sensitized allergic airway inflammation model revealed that DCT
significantly inhibited the increase of eosinophils in the airway and caused concentration-
dependent bronchorelaxation via a beta-2 adrenergic effect [41]. A randomized, double-blind
clinical trial [42] conducted to assess the add-on effect of DCT showed that AHR significantly
improved after weeks of DCT treatment compared with that after placebo use. In addition,
patients in the DCT group also showed superior clinical improvement and used less medica‐
tion than in the placebo group. This study suggested that addition of DCT to conventional
treatment could further improve AHR, even in patients with well-controlled asthma. How‐
ever, this study did not find a significant reduction in IgE levels and FEV1 with DCT treatment,
as compared to placebo [42].
6. Chinese single herbs use in children with asthma
We described several single herbs frequently used for asthmatic children in Taiwan (shown
in Table 2), including Zhe Bei Mu (Fritillaria thunbergii), Xing Ren (Semen Armeniacae Amarum),
Huang Qi (Astragalus membranaceus), Qian Hu (Peucedanum praeruptorum Dunn), Gan Cao
(Glycyrrhiza uralensis), Sang Bai Pi (Cortex mori radicis), Ban Xia (Pinellia ternate), Bo He (Mentha
haplocalyx), Da Huang (Rheum palmatum), Jie Geng (Platycodon grandiflorum), Huang Qin
(Scutellaria baicalensis), and Yu Xing Cao (Houttuynia cordata Thunb.).
6.1. Zhe Bei Mu
Zhe Bei Mu is used as an antitussive therapy and expectorant in TCM. Its extract inhibited
histamine release from rat peritoneal mast cells in a concentration-dependent manner.
Moreover, it also inhibits the production of inflammatory cytokines (IL-6, IL-8, and TNF-α) in
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human mast cell line-1 (HMC-1) cells and components of the mitogen-activated protein kinase
(MAPK) pathway in mast cells [43].
6.2. Xing Ren
Xing Ren has long been used in TCM to control acute lower respiratory tract infection and
asthma as a result of its expectorant and anti-asthmatic activities. Xing Ren was shown to have
anti-asthmatic activity and selectively inhibit the Th2 response in a mouse model by decreasing
eosinophils and IL-4 in the airway [44].
6.3. Huang Qi
Huang Qi has a long history of medicinal use for asthma treatment in China. It increases
metabolism and stimulates tissue regeneration, and it is used to treat colds, allergies, digestive
problems, and fatigue in TCM. Huang Qi was shown to inhibit the Th2 response. It significantly
reduced AHR, eosinophil counts, and IL-4, IL-5, and IL-13 levels and increased INF-γ levels
in BALF. Histological studies showed that Huang Qi markedly decreased inflammatory
infiltration, mucus secretion, and collagen deposition in lung tissues. CD4+CD25+Foxp3+
regulatory T cells (Tregs) play a significant role in the regulation of asthma, and the induction
of allergen-specific Tregs has become one appealing strategy for asthma therapy [45–47].
Huang Qi was shown to increase the population of CD4+CD25+Foxp3+ Tregs and promote
Foxp3 mRNA expression in a rat model of asthma [47]. This suggests that the anti-asthmatic
effects of Huang Qi are at least partially associated with CD4+CD25+Foxp3+ Tregs.
6.4. Qian Hu
Qian Hu is a TCM commonly used for the treatment of asthma. Its major constituents,
coumarins, were presumed to be responsible for its efficacy. Qian Hu was shown to reduce
AHR and airway eosinophilic inflammation significantly, improve pathologic lesions of the
lungs, reduce levels of IL-4, IL-5, and IL-13 in BALF and OVA-specific IgE in serum, inhibit
the expression of TGF-β1 in lungs, and upregulate levels of IL-10 and IFN-γ in BALF, as well
as the percentage of CD4+CD25+Foxp3+ regulatory T cells in the spleen [48, 49]. This suggests
that Qian Hu has great therapeutic potential for the treatment of allergic asthma.
6.5. Gan Cao
Gan Cao, commonly called “licorice,” is one of the most commonly used herbs in TCM. Airway
eosinophilic inflammation is a major feature of allergic asthma. Eotaxin-1 is involved in the
recruitment of eosinophils to sites of antigen-induced inflammation in asthmatic airways.
Licorice flavonoids can inhibit eotaxin-1 secretion by human fetal lung fibroblasts in vitro [50].
Licorice flavonoids also significantly reduced eosinophilic pulmonary inflammation, serum
IgE, IL-4, and IL-13 levels but also increased IFN-γ production in lung cell cultures in response
to antigen stimulation [51]. Glycyrrhizic acid is the main bioactive ingredient of licorice and
has been shown to exert anti-asthmatic effects by modulating Th1/Th2 cytokines (IL-4, IL-5,
IL-13 inhibition, IFN-γ increase in BALF) and enhancing CD4+CD25+Foxp3+ Tregs in OVA-
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sensitized mice [52]. Histological studies demonstrated that glycyrrhizic acid substantially
inhibited OVA-induced eosinophilia in lung and airway tissues [52].
6.6. Sang Bai Pi
Sang Bai Pi (Cortex mori radicis), the root epidermis of Morus alba L., has been traditionally used
for cough treatment in TCM. In OVA-induced asthma model mice [53], Sang Bai Pi significantly
reduced AHR, inhibited the production of histamine and IgE in serum, and decreased airway
eosinophil infiltration in BALF and lung tissue. Sang Bai Pi significantly attenuated the
secretion and mRNA levels of Th2 cytokines, such as IL-4, IL-5, and IL-13. In addition, Sang
Bai Pi significantly increased mRNA expression of IFN-γ, a Th1 cytokine. Furthermore, Sang
Bai Pi can exert anti-asthmatic effects by enhancing CD4+CD25+Foxp3+ Tregs.
6.7. Ban Xia
Ban Xia is a commonly used Chinese herb, with high bioactivity against cough and vomiting,
and eliminating the stagnation of phlegm. Ban Xia significantly attenuated OVA-induced
influx of the total number of leukocytes, eosinophils, neutrophils, macrophages, and lympho‐
cytes into the lungs, decreased airway mucus production, and attenuated levels of IL-4, IL-5,
IL-13, and TNF-α, in a dose-dependent manner. Ban Xia also significantly reduced the plasma
levels of histamine, total IgE and OVA-specific IgE [54, 55].
6.8. Bo He
Bo He has been reported to have pharmacological effects, including the lowering of body
temperature and relaxation of the muscles of the digestive tract. The herb is traditionally used
for the treatment of high fever, mild chills, cough, thirst, and sore throat and to combat nausea,
vomiting, and flatulence. Bo He significantly inhibited eosinophils, neutrophils, lymphocytes,
macrophages, and total cells in BALF of OVA-challenged mice. Bo He also decreased specific
IgE and Th2 cytokines, such as IL-4 and IL-5, in BALF and lung tissue. Airway inflammation
and hyperreactivity in asthma are likely to involve oxidative stress to the lung, and excess
production of reactive oxygen species (ROS) by immune cells may play an important role in
airway injury. An increase in the generation of ROS in the airway and BALF has been noted
in OVA-induced asthma models. Bo He has been shown to reduce the ROS in the BALF of
asthmatic model mice, as did montelukast, which has been used widely as an anti-asthmatic
drug [56].
6.9. Da Huang
Da Huang is used to cure stomach illness and as a “cathartic” to relieve severe constipation as
well as a poultice for fevers and edema caused by inflammation. Emodin, one of the major
compounds of Da Huang, displays a number of biological activities, such as anti-microbial,
immunosuppressive, anti-inflammatory, anti-tumor, and anti-atherosclerotic activities.
Moreover, emodin attenuates mast cell-dependent passive anaphylactic reactions in IgE-
sensitized mice. Emodin has also been shown to reduce IgE and Th2 cytokine levels in OVA-
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induced asthma mice. The inhibition of AHR by emodin may be associated with the reduction
of IL-4, IL-5, and IL-13 production and eosinophilia aggregation into the lungs [57].
6.10. Jie Geng
Jie Geng is commonly used as a cough suppressant and expectorant for treatment of common
colds, cough, sore throat, tonsillitis, and chest congestion. An aqueous extract of Jie Geng
inhibited OVA-specific IgE levels in BALF. Inflammatory cell infiltration and mucus hyper‐
secretion were also inhibited by Jie Geng extracts. Furthermore, Jie Geng extracts decreased
the generation of ROS in BALF, as well as NF-κB nuclear translocation in OVA-induced asthma
mouse model [58]. Jie Geng is abundant in saponins, which inhibit IgE antibody-induced
increases in IL-4 and TNF-α expression in RBL-2H3 cells. Saponins suppressed dinitrophenyl
(DNP)–IgE antibody–induced phosphorylation of Syk, and further downstream, Changkil
saponins (CKS) also inhibited the phosphorylation of Akt and MAPKs [59].
6.11. Huang Qin
Huang Qin is one of the most widely used medicinal herbs for the treatment of inflammation.
Ethanol extracts of Huang Qin may effectively suppress inflammation by downregulating the
expression of various inflammatory mediators (such as histamine) and reducing the produc‐
tion of inflammatory cytokines (such as IL-8 and TNF-α) as well as MAPK activation [60].
Skullcapflavone II is a flavonoid derived from Huang Qin (Scutellaria baicalensis). Skullcapfla‐
vone II significantly reduced AHR, airway eosinophilia, Th2 cytokine production, and TGF-
β1 levels in BALF and lungs in an OVA-induced asthma mouse model [61].
6.12. Yu Xing Cao
Yu Xing Cao is also used in folk medicine for diuresis and detoxification and for its anti-viral,
anti-bacterial, and anti-leukemic activities. It has been used for the treatment of cough,
pneumonia, bronchitis, uteritis, eczema, herpes simplex, acne, and chronic sinusitis. Ethanol
extracts of Yu Xing Cao downregulate the expression of IL-4, IL-5, thymus and activation-
regulated chemokine (TARC), and CCR4 receptor but do not have the same effect on IFN-γ [62].
Herbal name (Latin
name) Pictures Possible mechanisms
Zhe Bei Mu (Fritillaria
thunbergii)
Inhibits mast cell recruitment; decreases
serum IL-6, IL-8, and TNF-α; and
inhibits MAPK pathway [43]
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Herbal name (Latin
name) Pictures Possible mechanisms
Xing Ren (Semen
Armeniacae Amarum)
Decreases Th2 response; reduces IL-4
levels, eosinophilic inflammation, and
AHR [44]
Huang Qi (Astragalus
membranaceus)
Decreases Th2 response; increases IFN-γ
level; decreases IL-4, IL-5, IL-13, and
TGF-β1 levels; reduces eosinophilic and
neutrophilic inflammation; reduces
AHR, collagen deposition, and mucus
secretion; increases CD4+CD25+FoxP3+
regulatory T cells [45–47]
Qian Hu (Peucedanum
praeruptorum Dunn)
Decreases Th2 response; increases IFN-γ
and IL-10 levels; decreases IL-4, IL-5,
IL-13, specific IgE, and TGF-β1 levels;
reduces AHR, eosinophilic
inflammation; increases
CD4+CD25+FoxP3+ regulatory T cells [48,
49]
Gan Cao (Glycyrrhiza
uralensis)
Decreases Th2 response; increases IFN-
γ; decreases IL-4, IL-5, IL-13, specific
IgE, and eotaxin-1 levels; reduces
eosinophilic inflammation; increases
CD4+CD25+FoxP3+ regulatory T cells [50–
52]
Sang Bai Pi (Cortex mori
radicis)
Decreases Th2 response; decreases IL-4,
IL-5, IL-13, and specific IgE levels;
reduces AHR, eosinophilic
inflammation, and histamine release;
increases CD4+CD25+FoxP3+ regulatory T
cells [53]
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Herbal name (Latin
name) Pictures Possible mechanisms
Ban Xia (Pinellia ternate)
Reduces IL-4, IL-5, IL-13, specific IgE,
and TNF-α levels; reduces eosinophilic
inflammation and mucus production
[54, 55]
Bo He (Mentha haplocalyx)
Decreases Th2 responses; decreases IL-4,
IL-5, and specific IgE levels; reduces
eosinophilic inflammation and mucus
production [56]
Da Huang (Rheum
palmatum)
Decreases IL-4, IL-5, IL-13, and specific
IgE levels; reduces eosinophilic
inflammation [57]
Jie Geng (Platycodon
grandiflorum)
Decreases serum IgE, ROS scavenger;
decreases IL-4 and TNF-α; decreases
Syk-dependent cascades; inhibits MAPK
and Akt pathways [58, 59]
Huang Qin (Scutellaria
baicalensis)
Restores serum IL-8 and TNF-α; inhibits
MAPK pathways; decreases Th2
response; decreases IL-4, IL-5, IL-13,
specific IgE, and TGF-β1 levels; reduces
AHR and eosinophilic inflammation [60,
61]
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Herbal name (Latin
name) Pictures Possible mechanisms
Yu Xing Cao (Houttuynia
cordata Thunb.)
Decreases Th2 response; decreases IL-4,
IL-5, and TARC levels [62]
Table 2. Single herbs frequently used for asthmatic children
7. Acupuncture use in children with asthma
Acupuncture is a TCM therapeutic approach involving the stimulation of points on the body
by  using  needles.  For  thousands  of  years,  acupuncture  has  been  used  to  treat  several
conditions, including asthma. Other methods of stimulation are traditionally used, such as
electroacupuncture, laser acupuncture, and transcutaneous electrical nerve stimulation. There
is  evidence  that  acupuncture  can  reduce  eosinophils  in  peripheral  blood  and  decrease
secretory IgA (sIgA) and total IgA levels in the saliva and nasal secretions of patients with
allergic asthma [63]. The role of eosinophil activation in asthma has been well documented.
sIgA is a potent stimulus for eosinophils  and represents the main trigger for eosinophil
degranulation. After acupuncture treatment, the reduction of sIgA levels and the decrease in
the numbers of eosinophils may be associated with the amelioration of eosinophilic inflam‐
mation  in  patients  with  allergic  asthma [63].  The  numbers  of  CD3+,  CD4+,  and  CD8+  T
lymphocytes in the peripheral blood were significantly increased, without significant cortisol
changes, in patients with allergic asthma treated by acupuncture [63]. It has been shown that
electroacupuncture  is  prominent  in  promotion  of  CD4+CD25+FoxP3+  Tregs  in  an  OVA-
induced experimental model [64]. Furthermore, acupuncture has also been shown to inhibit
AHR, eosinophils, neutrophils, specific IgE, Th1 cytokines, and the NF-κB pathway in OVA-
induced experimental asthma [65].
8. Acupuncture point application
Acupuncture point application therapies, combining Chinese herbal medicine and acupunc‐
ture points, have been extensively applied for the treatment of allergic rhinitis (AR) and asthma
[66]. Summer acupuncture point application treatment, also known as San-Fu-Tie or San-Fu-
Jiu, is one type of direct moxibustion administered in the summer through the direct applica‐
tion of an irritating herbal paste to acupuncture points. The basic herbal prescription of San-
Fu-Tie is usually composed of Bai Jie Zi (Semen Sinapis Albae), Xi Xin (Herba Asari), Gan Sui
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(Radix Kansui), and Yan Hu Suo (Rhizoma Corydalis) [66, 67]. These herbs are ground into a
powder, mixed, and made into paste using stale ginger juice. The standard acupoints include
Fei-shu (BL-13) and Feng-men (BL-12), the meridians named Taiyang Bladder Meridian of Foot
[67]. Numerous studies have shown significant efficacy through acupoint stimulation in
treatment of asthma, such as improvement of lung function, a decrease in cytokines (IL-4, IL-6,
IL-8, and IL-10), and restoring the Th1/Th2 balance toward Th1 [66, 67]. Few adverse effects
have been reported, except for mild skin allergy, or local swelling and blisters.
9. Mind–body exercise
Mind–body exercise, such as tai chi, yoga, and meditation, may benefit people with chronic
diseases. Tai Chi Chuan (tai chi), a Chinese traditional mind–body exercise with low-to-
moderate exercise intensity, is thought to improve cardiopulmonary function in patients with
chronic disease. Tai Chi Chuan has been shown to improve pulmonary function of asthmatic
children [68]. Yoga training was reported to improve pulmonary function tests (FEV1 and
PEFR), quality of life, and decrease in the weekly number of asthma attacks, scores for drug
treatment, and peak flow rate [69–71]. Meditation has also been shown to be a useful adjunct
for treating asthma [72].
10. Further research
There is increasing evidence for the efficacy of TCM or other complementary therapies in the
treatment of children with asthma, but this is still insufficient evidence for making recom‐
mendations about the value of TCM as an asthma treatment, as well-designed double-blind,
randomized clinical trials are lacking.
11. Conclusion
Asthma is the leading cause of chronic illness and missed school days among childhood. In
addition to standard treatment, the use of complementary therapy is increasing. TCM is a
popular CAM in East Asia and throughout the world. There is increasing scientific evidence
demonstrating that TCM has potential for the treatment of childhood asthma.
12. Abbreviations
AHR: airway hyperresponsiveness
ASM: airway smooth muscle
BALF: bronchoalveolar lavage fluid(s)
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FEV1: forced expiratory volume in 1 second
FVC: forced vital capacity
GM-CSF: granulocyte-macrophage colony-stimulating factor
ICAM-1: intercellular adhesion molecule 1
ICS: inhaled corticosteroids
IFN-γ: interferon gamma
IL: interleukin
LABA: long-acting beta-adrenoceptor agonists
MAPK: mitogen-activated protein kinases
MCP: monocyte chemotactic protein
MIP: macrophage inflammatory protein
MMP: matrix metalloproteinase
NF-κB: nuclear factor-Kappa B
OVA: ovalbumin
PEFR: peak expiratory flow rate
RANTES: regulated on activation, normal T cell expressed and secreted
SABA: short-acting beta-2-adrenoceptor agonists
TARC: thymus and activation-regulated chemokine
TCM: Traditional Chinese medicine
TGF: transforming growth factors
TLRs: Toll-like receptors
TNF: tumor necrosis factor
VCAM-1: vascular cell adhesion molecule 1
VEGF: vascular endothelial growth factor
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